pulmonary surfactant


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

pulmonary surfactant

See surfactant, def. 2.

pulmonary surfactant

A lipoprotein secreted by type II alveolar cells that decreases the surface tension of the fluid lining the alveoli, permitting expansion. Synthetic lung surfactant is available for treating patients with respiratory distress syndrome. In obstetrics, fetal production of surfactant can be stimulated by administration of a glucocorticoid 24 to 48 hr before an inevitable preterm birth.
Synonym: lung surfactant See: betamethasone; lecithin-sphingomyelin ratio
See also: surfactant
References in periodicals archive ?
Toxic oxidant species and their impact on the pulmonary surfactant system.
In: Pulmonary Surfactant (Robertson B, van Golde LM, Batenburg JJ, eds).
Discovery) (Nasdaq small cap: DSCO, DSCOU) announces the initiation of a pivotal Phase 3 trial to evaluate the efficacy of the company's novel pulmonary surfactant, Surfaxin(R) (lucinactant), in the treatment of full-term infants with Meconium Aspiration Syndrome (MAS).
Excerpts from the publication are as follows: "'Cleansing' of the lungs with dilute synthetic pulmonary surfactant may offer a new, safe, and feasible approach to improve the outcome of ARDS patients.
Discovery) (NASDAQ: DSCO,DSCOU) announced today the beginning of patient enrollment in its pivotal Phase 2/3 trial to evaluate the efficacy of the company's novel pulmonary surfactant, Surfaxin(TM), in the treatment of Acute Respiratory Distress Syndrome (ARDS) from direct causes.
to initiate a pivotal Phase 2/3 trial to evaluate the efficacy of the company's novel pulmonary surfactant, Surfaxin(TM), in the treatment of Acute Respiratory Distress Syndrome (ARDS) from direct causes.
Discovery Labs' technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant.
Discovery Labs' technology platforms include a novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant.
Discovery believes that through its technology, pulmonary surfactants have the potential, for the first time, to be developed into a series of respiratory therapies for critical care and other hospitalized patients where there are few or no approved therapies available.
During this period]' his research on pulmonary surfactants further illuminated the ways in which surfactants are produced by lung cells, their importance in normal pulmonary function, and how they interact with chemicals and hormones.